drugset / Trial / NCT02343172

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

NCT02343172

Phase 1 Completed 74 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.

Timeline

Start
2015-03-13
Primary completion
2019-10-16
Completion
2019-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribociclib Small molecule Oral
Subject Siremadlin Small molecule Oral

Indications